Theriva Biologics Inc. (TOVX) - Total Liabilities
Based on the latest financial reports, Theriva Biologics Inc. (TOVX) has total liabilities worth $22.85 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Theriva Biologics Inc. (TOVX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Theriva Biologics Inc. - Total Liabilities Trend (1993–2025)
This chart illustrates how Theriva Biologics Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Theriva Biologics Inc. assets under control.
Theriva Biologics Inc. Competitors by Total Liabilities
The table below lists competitors of Theriva Biologics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wise Group AB
ST:WISE
|
Sweden | Skr132.58 Million |
|
Saga plc
LSE:SAGA
|
UK | GBX1.22 Billion |
|
Inventure Growth & Securities Limited
NSE:INVENTURE
|
India | Rs-2.76 Billion |
|
Diversified Energy Company PLC
LSE:DEC
|
UK | GBX5.17 Billion |
|
Ryvyl Inc
NASDAQ:RVYL
|
USA | $26.64 Million |
|
ENTYR Ltd
AU:ETR
|
Australia | AU$15.33 Million |
|
Cyngn Inc
NASDAQ:CYN
|
USA | $11.30 Million |
|
Origin Agritech Limited
STU:39O1
|
Germany | €168.09 Million |
Liability Composition Analysis (1993–2025)
This chart breaks down Theriva Biologics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Theriva Biologics Inc. (TOVX) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Theriva Biologics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Theriva Biologics Inc. (1993–2025)
The table below shows the annual total liabilities of Theriva Biologics Inc. from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $22.86 Million | +40.35% |
| 2024-12-31 | $16.29 Million | +4.92% |
| 2023-12-31 | $15.52 Million | -10.26% |
| 2022-12-31 | $17.30 Million | +248.94% |
| 2021-12-31 | $4.96 Million | +57.27% |
| 2020-12-31 | $3.15 Million | -45.16% |
| 2019-12-31 | $5.75 Million | +55.94% |
| 2018-12-31 | $3.69 Million | -83.43% |
| 2017-12-31 | $22.25 Million | +9.87% |
| 2016-12-31 | $20.25 Million | +27.82% |
| 2015-12-31 | $15.84 Million | +65.23% |
| 2014-12-31 | $9.59 Million | +833.59% |
| 2013-12-31 | $1.03 Million | +160.00% |
| 2012-12-31 | $395.00K | -5.28% |
| 2011-12-31 | $417.00K | -21.69% |
| 2010-12-31 | $532.48K | +0.20% |
| 2009-12-31 | $531.43K | -14.38% |
| 2008-12-31 | $620.72K | -63.22% |
| 2007-12-31 | $1.69 Million | +131.48% |
| 2006-12-31 | $729.02K | -65.99% |
| 2005-12-31 | $2.14 Million | -87.32% |
| 2002-12-31 | $16.90 Million | +51.68% |
| 2001-12-31 | $11.14 Million | +90.00% |
| 2000-12-31 | $5.86 Million | +33.96% |
| 1999-12-31 | $4.38 Million | +98.98% |
| 1998-12-31 | $2.20 Million | -24.14% |
| 1997-12-31 | $2.90 Million | +163.64% |
| 1996-12-31 | $1.10 Million | +175.00% |
| 1995-12-31 | $400.00K | -55.56% |
| 1994-12-31 | $900.00K | +350.00% |
| 1993-12-31 | $200.00K | -- |
About Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcin… Read more